An industry chapter · Life Sciences Tools & Services
Life Sciences Tools & Services
43 members, A to WAT, A to Z by ticker.
Gross profitability
median 25% — gross profit as a share of total assets, each member's median across its readable years; read on 30 of 43 members
Capital intensity
median 4.1% — capital expenditure as a share of revenue, each member's median across its readable years; read on 43 of 43 members
Net cash
20 of the 43 members with a readable debt line hold more cash and short-term investments than total debt
Figures describe the list as a group, from each member's own filed record; they name no
member and form no rank. A member missing an input is absent from that median, never counted
against the others.
From the latest filings · data as of July 9, 2026.
The Agilent CrossLab segment spans the entire lab with its extensive services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represents a broad range of offerings designed to serve customer needs across end-markets and applications.
Bio-Rad is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables.
Our novel smNGS platform technologies combined with our AI-enhanced integrated workflow, allows us to push the technology frontier forward and deliver on the full promise of non-invasive liquid biopsy.
We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels.
We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels.
We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, atopic dermatitis, uveal melanoma.
We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.
Fortrea Holdings Inc. is a leading global contract research organization, providing biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology and medical device customers.
Owner earnings 2021–2025$143M$28M$128M$237M$88M
Retained capitalPaid out $1.1B more than it earned over 2021–2025; annual owner earnings grew $51M.
Balance sheetNet debt against an operating loss, $878M
Therapy Selection Guardant360 CDx Test We believe our Guardant360 CDx test was the first comprehensive liquid biopsy test approved by the FDA, and is the market leading comprehensive liquid biopsy test, based on the number of tests ordered.
ICON is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations.
Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets.
IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries.
We offer a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research.
Labcorp Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
Devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats.
We are a commercial-stage precision diagnostics company providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care.
Medpace Holdings markets and Clinical Development Services Before a new drug can be commercialized, it often must undergo extensive pre-clinical and clinical testing and regulatory review to verify safety and efficacy.
NeoGenomics provides a wide range of oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts who specialize in pathology and oncology.
We have achieved a market leadership position through our nearly 45 years of industry innovation and experience, as well as our long-term, recurring revenue relationships with many of the healthcare industry's largest organizations.
We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions.
We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.
Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
UL Solutions Inc. is a global safety science leader that provides Testing, Inspection and Certification services and related software and advisory offerings to customers worldwide.
Owner earnings 2022–2025$208M$252M$287M$403M
Retained capitalPaid out $1.3B more than it earned over 2022–2025; annual owner earnings grew $65M.
Balance sheetModest net debt, $196M · dividend paid 4 of 4 yrs, cut at least once
Waters Corporation, a global leader in analytical instruments and software, has pioneered innovations in chromatography, mass spectrometry and thermal analysis serving life, materials and food sciences for more than 65 years.
Owner earnings 2023–2025$518M$675M$564M
Retained capitalnot read
Balance sheetModest net debt, $819M
The same four lines for every member, in strict ticker order; a figure that could not be read
renders as "not read," never as a mark against the record beside it. The header describes the
list and names no member; the entries carry no ranking and form no score. What a chapter
cannot carry — understanding of the business, and a price — is yours.
No company matches that. Try a ticker, or part of a name.
Loading the index…
Search all companies: United States, Japan, Europe, and ADRs.
↑↓ move · ↵ open · esc close